NCT07085702 - A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Streptococcal Infections

Interventions

BIOLOGICAL

Low dose Strep A Alum

Low dose Strep A Alum vaccine will be administered intramuscularly (IM)

BIOLOGICAL

Medium dose Strep A Alum

Medium dose Strep A Alum vaccine will be administered IM

BIOLOGICAL

High dose Strep A Alum

High dose Strep A Alum vaccine will be administered IM

BIOLOGICAL

Low dose Strep A AS37

Low dose Strep A AS37 vaccine will be administered IM

BIOLOGICAL

Medium dose Strep A AS37

Medium dose Strep A AS37 vaccine will be administered IM

BIOLOGICAL

High dose Strep A AS37

High dose Strep A AS37 vaccine will be administered IM

DRUG

Strep A Alum Placebo

Strep A Alum Placebo will be administered IM

Trial Locations (2)

RECRUITING

GSK Investigational Site, Botany

RECRUITING

GSK Investigational Site, Camberwell